Literature DB >> 26573664

Lipid profile among girls with systemic lupus erythematosus.

Daniele Machado1, Roseli O S Sarni1,2, Thaís T O Abad1, Simone G L Silva1, Eugênia J B Khazaal1, Sonia Hix2, Milena S G Correia2, Fabíola I Suano-Souza1,2, Claudio A Len1, Maria Teresa R A Terreri3.   

Abstract

The aim of the study was to describe biomarkers of lipid metabolism associated with increased cardiovascular risk and their correlation with disease variables and markers of inflammation in adolescent females with systemic lupus erythematosus (SLE). This cross-sectional controlled study evaluated 33 adolescent females with juvenile SLE and 33 healthy controls. Anthropometric data, SLE disease activity index (SLEDAI), medications, proteinuria, ultra-sensitive C-reactive protein (us-CRP), lipid profile (total cholesterol, LDL-c, HDL-c and triglycerides), apolipoproteins A and B (Apo A-I and B), paraoxonase, and myeloperoxidase were evaluated. Median age of the patients and the median disease duration were 16.7 years and 54 months, respectively. SLEDAI scores above 4 were observed in 11 (33.3 %) patients. Moreover, 12 (36.4 %) patients were overweight, and 5 (15.2 %) had low height for age ratios. Dyslipidemia was observed in 13 (39.4 %) patients and in 7 (21.2 %) controls with a decrease in HDL-c concentrations in SLE patients even after adjustment for their nutritional status. In the group with SLE, us-CRP concentrations were inversely correlated with LDL-c/ApoB ratio (p = 0.031). After multivariate regression analysis, the SLE group showed lower concentration of Apo A-I and a decreased LDL-c/ApoB ratio. SLE adolescent females with low disease activity, with preserved kidney function and on low dose of corticosteroids, regardless of nutritional status and food intake, have proatherogenic lipid biomarkers, which may contribute to an increased atherosclerotic risk.

Entities:  

Keywords:  Adolescents; Apolipoprotein A-I; Apolipoprotein B; Dyslipidemia; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2015        PMID: 26573664     DOI: 10.1007/s00296-015-3393-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  36 in total

1.  Utility of childhood non-high-density lipoprotein cholesterol levels in predicting adult dyslipidemia and other cardiovascular risks: the Bogalusa Heart Study.

Authors:  Sathanur R Srinivasan; Maria G Frontini; Jihua Xu; Gerald S Berenson
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

2.  A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

Authors:  Maureen McMahon; Brian J Skaggs; Jennifer M Grossman; Lori Sahakian; John Fitzgerald; Weng Kee Wong; Elaine V Lourenco; Nagesh Ragavendra; Christina Charles-Schoeman; Alan Gorn; George A Karpouzas; Mihaela B Taylor; Karol E Watson; Michael H Weisman; Daniel J Wallace; Bevra H Hahn
Journal:  Arthritis Rheumatol       Date:  2014-01       Impact factor: 10.995

3.  The frequency of high/moderate lipoprotein risk factor for coronary artery disease is significant in juvenile-onset systemic lupus erythematosus.

Authors:  A L S Hayata; E F Borba; E Bonfá; J A L Kochen; C Goldenstein-Schainberg
Journal:  Lupus       Date:  2005       Impact factor: 2.911

4.  Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.

Authors:  M M Radwan; D El-Lebedy; R Fouda; E Elsorougy
Journal:  Clin Rheumatol       Date:  2014-04       Impact factor: 2.980

5.  Assessment of nutritional status and physical activity in systemic lupus erythematosus patients.

Authors:  Fabiana de Miranda Moura dos Santos; Mariane Curado Borges; Maria Isabel Toulson Davisson Correia; Rosa Weiss Telles; Cristina Costa Duarte Lanna
Journal:  Rev Bras Reumatol       Date:  2010 Nov-Dec

Review 6.  Management of dyslipidemia in children and adolescents with systemic lupus erythematosus.

Authors:  S P Ardoin; C Sandborg; L E Schanberg
Journal:  Lupus       Date:  2007       Impact factor: 2.911

Review 7.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 8.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

Review 9.  Is atherosclerosis accelerated in systemic sclerosis? Novel insights.

Authors:  Alessandra Soriano; Antonella Afeltra; Yehuda Shoenfeld
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

Review 10.  Cardiovascular risk in pediatric-onset rheumatological diseases.

Authors:  Julie Barsalou; Timothy J Bradley; Earl D Silverman
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  8 in total

1.  Association between ischemic heart disease and systemic lupus erythematosus-a large case-control study.

Authors:  Abdulla Watad; Arsalan Abu Much; Danielle Bracco; Naim Mahroum; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 2.  Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk.

Authors:  George A Robinson; Ines Pineda-Torra; Coziana Ciurtin; Elizabeth C Jury
Journal:  Front Med (Lausanne)       Date:  2022-05-31

3.  Lipid profiles and their potential inflammatory effects in anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Fei Liu; Baojie Wang; Chunjuan Wang; Bingbing Zhang; Shougang Guo
Journal:  Neurol Sci       Date:  2020-11-20       Impact factor: 3.307

4.  Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus.

Authors:  Kirsty E Waddington; George A Robinson; Leda Coelewij; Elvira Chocano; Thomas McDonnell; Filipa Farinha; Junjie Peng; Pierre Dönnes; Edward Smith; Sara Croca; Jyoti Bakshi; Maura Griffin; Andrew Nicolaides; Anisur Rahman; Elizabeth C Jury; Ines Pineda-Torra
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-04       Impact factor: 10.514

5.  Coagulation cascade and complement system in systemic lupus erythematosus.

Authors:  Yan Liang; Shang-Bo Xie; Chang-Hao Wu; Yuan Hu; Qin Zhang; Si Li; Yin-Guang Fan; Rui-Xue Leng; Hai-Feng Pan; Hua-Bao Xiong; Dong-Qing Ye
Journal:  Oncotarget       Date:  2017-12-11

Review 6.  Lipid Metabolism: Immune Regulation and Therapeutic Prospectives in Systemic Lupus Erythematosus.

Authors:  Wei Sun; Pengchong Li; Jianping Cai; Jie Ma; Xuan Zhang; Yong Song; Yudong Liu
Journal:  Front Immunol       Date:  2022-03-18       Impact factor: 7.561

7.  Elevated ApoB/ApoA-I ratio is associated with acute anti-N-Methyl-D-aspartate receptor encephalitis, but not disease outcomes.

Authors:  Yingying Liu; Xiaomeng Ma; Lili Ma; Zhumin Su; Donghong Li; Xiaohong Chen
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

Review 8.  High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy.

Authors:  Sang Yeop Kim; Minzhi Yu; Emily E Morin; Jukyung Kang; Mariana J Kaplan; Anna Schwendeman
Journal:  Arthritis Rheumatol       Date:  2019-11-26       Impact factor: 10.995

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.